NCT05233397 2026-04-08
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Nationwide Children's Hospital
Phase 2 Recruiting
Clinical Trials
8 trialsNCT03999749 2026-03-09
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
Phase 2 Active not recruiting
NCT04940299 2026-03-06
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05972135 2026-02-23
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
SCRI Development Innovations, LLC
Phase 2 Recruiting
NCT03970226 2026-02-17
Tocilizumab in Children With ACP
University of Colorado, Denver
Phase EARLY_PHASE1 Active not recruiting
NCT05391750 2026-02-17
Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
Emory University
Phase 1 Active not recruiting
NCT04375228 2026-02-06
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
Columbia University
Phase 2 Active not recruiting
NCT05846789 2026-01-21
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Indiana University
Phase 2 Recruiting